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ABSTRACT
Background. Among salivary gland malignancies, the
prognosis of salivary duct carcinoma (SDC) is assumed to
be the poorest. However, because of its low incidence,
reliable survival estimates and prognostic factors based on
a large number of patients remain to be elucidated, thereby
making it impossible to standardize the optimal treatment
for SDC.
Methods. We performed this multi-institutional, retro-
spective analysis by collecting the clinical information of
141 patients with SDC without distant metastasis who
underwent curative surgery as the initial treatment to elu-
cidate overall survival (OS) and disease-free survival
(DFS) along with their prognostic factors.
Results. The 3-year OS and DFS rates were 70.5 and
38.2 %, respectively. Multivariate analysis revealed that
age C65 years (p\ 0.001) and N1 and N2 (p = 0.047 and
\0.001, respectively) were independent prognostic factors
for OS, whereas the primary site of the minor salivary and
sublingual gland (p\ 0.001) and N2 (p\ 0.001) were
those for DFS. The most common treatment failure was
distant metastasis (55 patients, 39.0 %). For early parotid
SDC, neither total parotidectomy in the patients with early
T stage nor nerve resection in the patients without facial
nerve palsy showed survival benefits.
Conclusions. Advanced N stage independently affects
both OS and DFS. Partial parotidectomy with facial nerve
preservation could be a less invasive standard surgical
procedure for parotid gland SDC in the early T stage
without facial nerve palsy. Effective systemic therapy is
imperative to improve DFS of SDC.
Salivary duct carcinoma (SDC), an aggressive and rel-
atively rare tumor arising from the ductal epithelium of the
salivary gland, represents approximately 10 % of all sali-
vary gland malignancies.1,2 Although SDC was first
reported by Kleinsasser in 1968, it was officially defined as
a distinctive clinicopathologic entity in the revised histo-
logic classification of salivary gland neoplasms by the
World Health Organization in 1990.3,4 SDC morphologi-
cally resembles ductal carcinoma of the breast while
considering the histological features, such as ductal
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formation with a solid, cystic, cribriform, or papillary
structure; elements of intraductal comedonecrosis; calcifi-
cation; and a reactive desmoplastic stroma.1,2,5,6 In general,
SDC tends to be diagnosed in men in their 60s or 70s
predominantly in the parotid gland, which is the most
common primary site.1,2,7,8 Clinically, SDC is character-
ized by aggressive behavior with a tendency for rapid
progression, including early facial nerve involvement,
extra-glandular invasion, and high incidence of regional
and distant metastasis, leading to tumor-related death.7–10
Similar to other high-grade salivary gland tumors, the
standard treatment for resectable tumors is radical surgery,
including ipsilateral neck dissection, followed by postop-
erative adjuvant radiotherapy. Unfortunately, because of
the high incidence of locoregional recurrence and distant
metastases, the latter reportedly being 40–70 %, most
patients die of the disease within 3 years. Hence, the
prognosis of SDC appears to be one of the poorest among
salivary gland cancers.6,8–13 However, due to its very low
incidence, these previous studies on clinical outcomes with
survival analysis have been performed in a small number of
patients, ranging from 13 to 56. Thus, reliable survival
estimates and prognostic factors of SDC based on a large
number of patients remain to be clarified, except for a
recent study that analyzed the data from the Surveillance,
Epidemiology and End Results (SEER) program of the
National Cancer Institute.14 For the same reason, it remains
impossible to conduct large-scale clinical trials to discover
a promising chemotherapy protocol for patients with SDC
or other salivary gland malignancies.
To overcome the inevitable limitations of single-insti-
tute clinical investigations, we organized a multi-
institutional research group to collect the clinical and
histopathological information from a large number of
patients with SDC. We performed this retrospective anal-
ysis to elucidate the clinical prognostic factors along with
the clinical outcomes of the patients with SDC treated with
curative intent at seven tertiary hospitals.
METHODS
Patients and Treatments
The present study was approved by the Institutional
Ethics Review Board of each of the seven institutions that
participated in the study; the requirement for obtaining
informed consent was waived owing to the retrospective
nature of the analysis. The clinical data of 186 patients with
SDC diagnosed at those institutions between 1992 and
2014 were obtained, of which 141 patients without distant
metastasis at initial diagnosis who underwent curative
surgery as the initial treatment were enrolled in this study.
All patients underwent central pathological review by two
expert pathologists (T.N. and Y.S.) and were staged
according to the UICC TNM classification and staging
system (2010, 7th edition).15
The surgical procedure for the primary tumor was
determined according to the tumor site and its extent,
which were precisely evaluated by imaging diagnosis using
CT, MRI, US, and/or PET-CT. Neck dissection was per-
formed for patients with lymph node metastasis (N1 and
N2 patients) and/or those (including N0 patients) with
histopathological diagnosis of high-grade malignancy
indicated preoperatively by aspiration cytology. Postoper-
ative radiotherapy of 60–66 Gy was given when any of the
resection margins was positive or equivocal and/or lymph
node metastasis was pathologically positive. In cases of
grossly positive margins and/or extracapsular spread, con-
current chemoradiotherapy or adjuvant chemotherapy was
administered at the surgeon’s discretion.
Statistical Analysis
Overall survival (OS) and disease-free survival (DFS)
rates were estimated using the Kaplan–Meier method. The
prognostic effects of patient/disease factors, including age,
sex, primary site, tumor size, facial nerve palsy, N classi-
fication, rapid tumor progression (defined as a rapid growth
of the primary tumor as observed by the patient immedi-
ately prior to visiting a clinic or hospital), and pain (defined
as a pain that the patient had in the lesion), were first
examined by univariate analysis using the log-rank test and
the Cox’s proportional hazards model; the latter further
assessed the independent significance of these factors on
multivariate analysis without sequential and/or stepwise
variable selection. p values\0.05 were considered statis-
tically significant. All statistical analyses were performed
using STATA ver. 13 (StataCorp., TX).
We also investigated the patterns of treatment failure,
including locoregional recurrence and distant metastasis.
To evaluate the possible validity of less invasive proce-
dures for SDC of the parotid gland in the early T stage and/
or without facial nerve palsy, we examined differences in
the clinical outcomes including locoregional control (LRC)
rate between patients who underwent partial parotidectomy
and total parotidectomy, as well as those between nerve
preservation and nerve resection.
RESULTS
Patient Characteristics
The clinical and demographic characteristics of the 141
patients that comprised 119 men (84.4 %) and 22 women
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(15.6 %) are summarized in Table 1. The median age at
initial diagnosis was 64 (range 26–85) years. The primary
tumor site was the parotid gland in 112 patients (79.4 %),
submandibular gland in 25 (17.7 %), minor salivary gland
in 3 (2.1 %), and sublingual gland in 1 (0.7 %). Approxi-
mately two-thirds of the patients (93 patients, 66.0 %)
presented with a T3/T4 tumor. Lymph node metastasis was
clinically positive (N1/N2) in more than a half of the
patients (71 patients, 50.4 %). Among the 138 patients with
primary tumor size information, 85 patients had tumors
\40 mm in size and 53 patients had tumors C40 mm.
Forty-three patients (30.5 %) presented with facial nerve
palsy, all of whom had primary tumors at the parotid gland.
Thirty-four patients (24.1 %) had a recent history of rapid
progression of the tumor, and 25 patients (17.7 %) expe-
rienced pain due to the tumor.
While 83 patients underwent surgery followed by
adjuvant radiotherapy or chemoradiotherapy, 51 patients
underwent surgery alone, and the remaining 7 patients
received adjuvant chemotherapy without radiotherapy.
Surgical procedures were extended total parotidectomy
(composite resection of the parotid gland along with sur-
rounding structures) in 31 patients, total parotidectomy in
60, partial parotidectomy (lobectomy) in 19, parapharyn-
geal tumorectomy in 4, submandibular gland resection in
25, and partial maxillectomy and extended sublingual
gland resection in 1 each.
Clinical Outcome and Survival Analysis
The median follow-up period was 36 months. At the
time of analysis, 55 patients were alive without the disease
(including 7 patients who underwent secondary or tertiary
salvage treatment and remained recurrence-free), 44 died
of disease recurrences (2 of local, 1 of local and distant, 2
of regional, 7 of regional and distant, 25 of distant, 1 of
treatment-related, and 6 unspecified), 29 patients were
alive with the disease, and 13 died of other causes. The 3-
year OS and DFS rates were 70.5 % [95 % confidence
interval (CI) 61.4–77.8 %] and 38.2 % (95 % CI 29.5–
46.9 %), respectively (Fig. 1a, b).
The results of the univariate analysis for the prognostic
factors determined by log-rank tests are displayed, in part,
in Fig. 1c–f, whereas those analyzed by Cox’s hazards
model are summarized in Table 2. The OS was signifi-
cantly worse in patients aged C65 years (p = 0.002, vs.
\65 years), those with N1 and N2 (p = 0.036 and\0.001,
respectively, vs. N0), and those showing rapid progression
(p = 0.003), whereas no significant difference was found
regarding other factors. The DFS was significantly worse
when primary tumors were at the minor salivary gland and
sublingual gland (p = 0.009, vs. the parotid gland), in
patients with N2 (p\ 0.001, vs. N0), those showing rapid
progression (p = 0.014), and those with pain (p = 0.032),
whereas other factors showed no significant difference.
Multivariate analysis revealed that age C65 years [hazard
ratio (HR) = 2.96, p\ 0.001, vs.\65 years] and N1 and
N2 (HR = 2.97 and 4.01, p = 0.047 and\0.001, respec-
tively, vs. N0) were independent prognostic factors for OS,
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FIG. 1 Actuarial survival curves of patients with SDC. a Overall
survival (OS) and b disease-free survival (DFS) of all 141 patients
with SDC. The 3-year OS and DFS rates were 70.5 and 38.2 %,
respectively. The survival curves according to each of the prognostic
factors that were found to be significant on both univariate analysis
with the log-rank test and multivariate analysis with Cox’s hazards
model are shown as follows: c, d OS according to age (p = 0.002)
and N classification (shown as cN, p\ 0.001), respectively. e, f DFS
according to primary tumor site (p = 0.017) and N classification
(shown as cN, p\ 0.001), respectively
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while the primary sites of the minor salivary gland and
sublingual gland (HR = 8.46, p\ 0.001, vs. the parotid
gland) and N2 (HR = 3.94, p\ 0.001, vs. N0) were
independent prognostic factors for DFS (Table 2).
Patterns of Treatment Failure
As shown in Fig. 2, treatment failure occurred in 78
patients (55.3 %), including 13 (9.2 %) local, 18 (12.8 %)
regional, and 55 (39.0 %) distant failures, of which 48 were
without locoregional failure. The most common sites of
distant metastasis were the lungs (n = 32), followed by the
bones (n = 11), liver (n = 5), and brain (n = 3).
Partial Parotidectomy vs. Total Parotidectomy for
Parotid SDC in the Early T Stage
The clinical outcomes of 33 patients with SDC of T1-2 of the
parotid gland who underwent partial parotidectomy or total
parotidectomy were compared (Table 3a). Univariate analysis,
as well as multivariate analysis adjusted for age, sex, tumor size,
N classification, rapid progression, pain, and adjuvant radio-
therapy, showed no significant difference in OS, DFS, and LRC.
TABLE 2 Univariate and multivariate analysis for overall survival and disease-free survival (n = 141)
Variables N Overall survival Disease-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value
Age
\65 78 1.00 – – 1.00 – – 1.00 – – 1.00 – –
C65 63 2.33 1.36–3.99 0.002* 2.96 1.62–5.41 \0.001* 1.20 0.78–1.86 0.405 1.62 0.98–2.68 0.058
Sex
Men 119 1.00 – – 1.00 – – 1.00 – – 1.00 – –
Women 22 0.96 0.47–1.97 0.916 1.38 0.60–3.19 0.448 0.69 0.36–1.34 0.276 0.71 0.34–1.49 0.370
Primary tumor site
Parotid gland 112 1.00 – – 1.00 – – 1.00 – – 1.00 – –
Submandibular gland 25 1.17 0.60–2.27 0.648 1.37 0.59–3.16 0.459 1.03 0.59–1.82 0.906 1.48 0.72–3.05 0.284
Others 4 1.54 0.37–6.39 0.551 1.54 0.29–8.17 0.613 3.98 1.42–11.15 0.009* 8.46 2.61–27.45 \0.001*
Tumor size
\40 mm 85 1.00 – – 1.00 – – 1.00 – – 1.00 – –
C40 mm 53 1.32 0.76–2.33 0.324 1.03 0.54–1.96 0.931 1.36 0.86–2.13 0.185 1.29 0.77–2.16 0.339
Unknown 3 – – – – – – – – – – – –
Facial nerve palsy
- 96 1.00 – – 1.00 – – 1.00 – – 1.00 – –
? 43 1.39 0.80–2.40 0.239 1.50 0.77–2.94 0.233 1.49 0.95–2.35 0.085 1.69 0.99–2.88 0.054
Unknown 2 – – – – – – – – – – – –
N classification
0 70 1.00 – – 1.00 – – 1.00 – – 1.00 – –
1 9 2.70 1.07–6.80 0.036* 2.97 1.02–8.70 0.047* 2.12 0.91–5.36 0.078 1.92 0.71–5.18 0.195
2 62 3.29 1.83–5.91 \0.001* 4.01 2.04–7.90 \0.001* 4.05 2.51–6.55 \0.001* 3.94 2.34–6.63 \0.001*
Rapid progression
- 101 1.00 – – 1.00 – – 1.00 – – 1.00 – –
? 34 2.40 1.36–4.24 0.003* 1.73 0.87–3.42 0.116 1.82 1.13–2.93 0.014* 1.18 0.68–2.07 0.556
Unknown 6 – – – – – – – – – – – –
Pain
- 112 1.00 – – 1.00 – – 1.00 – – 1.00 – –
? 25 1.51 0.82–2.78 0.182 1.34 0.63–2.84 0.451 1.74 1.05–2.89 0.032* 1.78 0.94–3.35 0.076
Unknown 4 – – – – – – – – – – – –
HR hazard ratio, CI confidence interval
* Statistically significant (p\ 0.05)
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Nerve Preservation vs. Nerve Resection for Parotid
SDC Without Facial Nerve Palsy
The clinical outcomes of 68 patients with SDC without
facial nerve palsy who underwent surgery with nerve
preservation or nerve resection were compared (Table 3b).
Univariate analysis showed that OS, DFS, and LRC of the
patients who underwent facial nerve resection were sig-
nificantly worse than those whose facial nerves were
preserved. However, no significant difference was found in
OS, DFS, and LRC, on multivariate analysis adjusted as
described above.
DISCUSSION
There has been an absence of studies analyzing the
survival and prognostic factors of SDC based on a large
number of patients because of its low incidence. To the
best of our knowledge, the present study analyzed the
largest series of patients with SDC, except for a U.S. study
using the SEER data in which only disease-specific sur-
vival (DSS) was described.14 Although the retrospective
nature of the study inevitably could not exclude selection
bias, especially for additional treatment after surgery, the
results obtained from our study could provide reliable
survival estimates and prognostic factors for patients with
SDC.
Two early studies with small cohorts (n = 26 each) in
the 1990s reported considerably poor outcomes of 2-year
OS of 42.3 and 58 %, and 5-year OS of 11.5 and 30 %,
FIG. 2 Distribution of treatment failure patterns in 141 patients with
SDC. Thirteen cases (9.2 %) of local, 18 cases (12.8 %) of regional,
and 55 cases (39.0 %) of distant failures were observed in a total of 78
patients
TABLE 3 The impact of total parotidectomy in early T stage SDC (n = 33) and facial nerve resection in facial nerve palsy-negative SDC
(n = 68) of the parotid gland on clinical outcome
(a) Early T stage SDC of the parotid gland (n = 33)
Endpoint Procedure N Univariate analysis Multivariate analysisa
Extent of parotidectomy HR 95 % CI p value HR 95 % CI p value
Overall survival Partial 15 1.00 – – 1.00 – –
Total 18 1.24 0.29–5.21 0.771 not calculable – –
Disease-free survival Partial 15 1.00 – – 1.00 – –
Total 18 1.60 0.48–5.32 0.443 0.18 0.01–2.83 0.225
Locoregional control Partial 15 1.00 – – 1.00 – –
Total 18 2.16 0.22–20.90 0.507 not calculable – –
(b) Facial nerve palsy-negative SDC of the parotid gland (n = 68)
Endpoint Procedure N Univariate analysis Multivariate analysisa
Facial nerve HR 95 % CI p value HR 95 % CI p value
Overall survival Preservation 27 1.00 – – 1.00 – –
Resection 41 2.92 1.08–7.90 0.035* 0.91 0.23–3.53 0.890
Disease-free survival Preservation 27 1.00 – – 1.00 – –
Resection 41 3.54 1.54–8.16 0.003* 2.10 0.71–6.21 0.179
Locoregional control Preservation 27 1.00 – – 1.00 – –
Resection 41 4.57 1.02–20.47 0.047* 1.63 0.26–10.23 0.604
HR hazard ratio, CI confidence interval
* Statistically significant (p\ 0.05)
a Adjusted by age, sex, tumor size, N classification, rapid progression, pain, and adjuvant radiotherapy
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respectively.8,10 Although a later study with a larger cohort
(n = 59) also showed a comparable outcome of the 2-, 3-,
and 5-year OS of 62.3, 42.7, and 26.9 %, respectively,
more recent studies with similar cohort sizes reported
somewhat better 5-year OS outcomes of 55.1 % (n = 35),
42 % (n = 56), and 43 % (n = 54), suggesting the benefit
of intensification of both surgery and adjuvant radiotherapy
regarding the treatment outcomes.12,13,16,17 However, there
were noticeably large differences between OS and DFS,
i.e., the 5-year DFS was 29 %.12 In our study, the 3-year
OS and DFS were 70.5 and 38.2 %, respectively. This
reflected a considerably high ratio of treatment failure
(55.3 % in our study) for this disease.
Multivariate analysis in the present study showed, for the
first time, that advanced N stage independently affects both
OS and DFS in patients with SDC. Significant correlation of
the N classification with OS has been previously reported,
although those results were based on only univariate anal-
yses with much smaller sample sizes.8,10,16 Our findings
also were partially consistent with those of the SEER study
(n = 228), in which multivariate analysis showed that age
and N classification, as well as tumor size and grade, were
independent prognostic factors for OS and DSS (DFS was
not analyzed).14 Although the influence of age on prognosis
may depend on the cancer type, the prognostic significance
revealed in the OS of patients with SDC may reflect an
increased risk of death in the elderly owing to other fatal
diseases generally associated with aging.
In an early study of 30 patients with SDC that included
13 patients with distant metastasis at initial diagnosis,
multivariate analysis showed that tumor diameter and dis-
tant metastasis were independent prognostic factors for
OS.18 Given that some subjects had distant metastasis,
unlike most other studies, distant metastasis could inevi-
tably be the most unfavorable predictor of survival unless
an effective systemic therapy becomes available for such
patients. In another recent study that employed multivariate
analysis, lymphovascular invasion and perineural invasion
were found to be independent histopathological prognostic
factors for OS, suggesting a possible benefit of evaluating
histopathological characteristics for predicting survival of
patients with SDC.17
In our cohort, the most common form of treatment failure
was distant metastasis, which corroborates the findings of a
limited number of previous observations in smaller
cohorts.13,17 Consistent with our findings, the lungs and bones
were the most common sites of distant metastasis in
SDC.11,13,17 Such a high ratio of distant metastasis is pre-
sumed to be the leading cause of low DFS. Although extended
resection with wider margins combined with intensified
adjuvant radiotherapy have seemingly contributed to better
treatment outcomes of SDC by improving LRC, these
strategies alone cannot prevent the development of delayed
distant metastasis. Therefore, an effective systemic therapy
after curative surgery is imperative to improve DFS of SDC
patients. Unfortunately, there has been no evidence-based
chemotherapy regimen for salivary gland cancers including
SDC.19 Recent immunohistochemical studies reported that
androgen receptor (AR) expression is observed in 43–92 % of
SDC, whereas HER2 expression is observed in 26–77 %, both
of which were confirmed in our separated subanalysis (data
not shown), suggesting a potential role for agents acting on
these receptors as possible molecular-targeted therapy for
SDC.16,20–31 Currently, our multi-institutional joint research
group is conducting interventional clinical studies of systemic
therapy targeting AR and HER2 in combination with
chemotherapy for recurrent/metastatic SDC.
Although preservation of the facial nerve has been rec-
ommended during parotid gland cancer surgery if nerve
function was preoperatively normal, its applicability for
SDC remains to be determined.32,33 In our subanalyses
regarding patients with early SDC of the parotid gland,
neither total parotidectomy in patients with early T stage
nor nerve resection in patients without facial nerve palsy
showed a survival benefit compared with those treated with
partial parotidectomy and nerve preservation, respectively.
Although these results should be interpreted while consid-
ering the possible selection bias because of the retrospective
nature of the study, our results suggest that even in SDC of
the parotid gland, partial parotidectomy with facial nerve
preservation could be the standard procedure for primary
tumors in early T stage without facial nerve palsy.
CONCLUSIONS
Our multi-institutional joint study revealed that
advanced N stage independently affects both OS and DFS.
Given the high incidence of distant failure, an effective
systemic therapy is essential for improving DFS of SDC.
Partial parotidectomy with facial nerve preservation may
constitute a less invasive standard surgical procedure for
parotid gland SDC in the early T stage without facial nerve
palsy.
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